

Supporting Information for
Design, Synthesis and Anti-cervical Cancer Activity of Aroylpyrrole-Based
Derivatives as Potent Histone Deacetylase 6 Inhibitors

Xingjie Wang^a, Lixuan Du^b, Yaxin Xue^c, Yitong Su^c, Xuetao Yuan^a, Shuting Yang^a, Weiyi Su^c, Wenli Gou^{c,*}, Xin Chen^{d,*}, Lu Zong^{c,*}

^a*Department of General Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, P. R. China*

^b*Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, P. R. China*

^c*Department of Obstetrics & Gynecology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, P. R. China*

^d*Shaanxi Key Laboratory of Natural Products & Chemical Biology, College of Chemistry & Pharmacy, Northwest A&F University, Yangling 712100, P. R. China*

Corresponding Author

*Wenli Gou

E-mail: 13572870556@126.com; Fax: +86-029-85323338

*Xin Chen

E-mail: chenxin1888@nwsuaf.edu.cn; Fax: +87-029-87092335

*Lu Zong



E-mail: catherazong@163.com; Fax: +86-029-85323338

Notes


The authors declare no competing interest.


¹H-NMR, ¹³C-NMR and HRMS spectra of synthesized compounds of **10a-k** and **11a-g**.....Page 2-25.
Representative graphs for **10g**.....Page 26.

5-benzoyl-*N*-(7-(hydroxyamino)-7-oxoheptyl)-1-methyl-1*H*-pyrrole-2-carboxamide (**10a**)





264-16 #20 RT: 0.11 AV: 1 NL: 1.53E6
T: FTMS + p ESI Full lock ms [80.0000-1200.0000]







5-benzoyl-1-(cyclopropylmethyl)-*N*-(7-(hydroxyamino)-7-oxoheptyl)-1*H*-pyrrole-2-carboxamide
(10b)







264-15 #16 RT: 0.09 AV: 1 NL: 2.39E8
T: FTMS + p ESI Full lock ms [80.0000-1200.0000]



5-benzoyl-1-(3-chlorobenzyl)-*N*-(6-(hydroxyamino)-6-oxohexyl)-1*H*-pyrrole-2-carboxamide (**10c**)



DBY-1-181-1.10.fid
PROTON DMSO (\\192.168.1.100\nmrdata\chenxin) test 16







5-benzoyl-1-(3-chlorobenzyl)-*N*-(7-(hydroxyamino)-7-oxoheptyl)-1*H*-pyrrole-2-carboxamide (**10d**)

DBY-1-180-1.10.fid
 PROTON DMSO (\\192.168.1.100\nmrdata\chenxin) test 15




264-4 #19 RT: 0.10 AV: 1 NL: 3.79E6
 T: FTMS + p ESI Full lock ms [80.0000-1200.0000]








5-benzoyl-1-(4-chlorobenzyl)-*N*-(7-(hydroxyamino)-7-oxoheptyl)-1*H*-pyrrole-2-carboxamide (**10e**)






264-12 #19 RT: 0.10 AV: 1 NL: 1.99E6
T: FTMS + p ESI Full lock ms [80.0000-1200.0000]




5-benzoyl-1-(2-chlorobenzyl)-*N*-(7-(hydroxyamino)-7-oxoheptyl)-1*H*-pyrrole-2-carboxamide (**10f**)












264-9 #20 RT: 0.11 AV: 1 NL: 1.39E7
T: FTMS + p ESI Full lock ms [80.0000-1200.0000]





—— 从B中减去基线


5-benzoyl-*N*-(7-(hydroxyamino)-7-oxoheptyl)-1-(4-(trifluoromethyl)benzyl)-1*H*-pyrrole-2-carboxamide (**10h**)




5-benzoyl-1-benzyl-N-(7-(hydroxyamino)-7-oxoheptyl)-1H-pyrrole-2-carboxamide (**10i**)








5-benzoyl-*N*-(7-(hydroxyamino)-7-oxoheptyl)-1-(4-methoxybenzyl)-1*H*-pyrrole-2-carboxamide (**10k**)



Mass spectrum of compound 17. The x-axis represents the mass-to-charge ratio (m/z) from 470 to 540, and the y-axis represents the relative abundance from 0 to 100. The base peak is at m/z 500.21552. Other labeled peaks include m/z 463.30310, 473.34500, 478.23401, 484.22116, 489.72003, 497.19479, 502.22159, 507.32846, 516.18982, 522.19745, 532.15295, and 540.14728.

m/z	Relative Abundance (approx.)
463.30310	1
473.34500	1
478.23401	20
484.22116	2
489.72003	1
497.19479	5
500.21552	100
502.22159	30
507.32846	5
516.18982	1
522.19745	1
532.15295	1
540.14728	1




Chemical shift (ppm): 8.73, 8.71, 8.69, 7.69, 7.66, 7.46, 7.44, 7.42, 7.40, 7.33, 7.31, 7.27, 7.03, 4.38, 4.37, 3.88, -2.50 (TMS).



Integration values (from left to right): 0.05, 0.05, 1.00, 1.00, 1.00, 1.00, 2.00, 2.00, 2.00.

Peak assignments (from left to right):

- J (a): 11.39
- I (a): 11.16
- B (c): 8.71
- F (d): 7.32
- D (a): 7.09
- C (d): 7.08
- G (b): 7.03
- E (a): 7.43
- A (d): 4.37
- H (a): 3.88




264-1#18 RT: 0.10 AV: 1 NL: 1.85E6
T: FTMS + p ESI Full lock ms [80.0000-1200.0000]




5-benzoyl-1-(cyclopropylmethyl)-*N*-(4-(hydroxycarbamoyl)benzyl)-1*H*-pyrrole-2-carboxamide (**11b**)


DBY-1-165-1.10.fid
 PROTON DMSO (\\192.168.1.100\nmrdata\chenxin) test 11




DBY-1-165-1.30.fid
 C13CPD DMSO (\\192.168.1.100\nmrdata\chenxin) test 22




264-2 #16 RT: 0.09 AV: 1 NL: 6.39E5
 T: FTMS + p ESI Full lock ms [80.0000-1200.0000]






5-benzoyl-1-(3-chlorobenzyl)-*N*-(4-(hydroxycarbamoyl)benzyl)-1*H*-pyrrole-2-carboxamide (**11c**)



DBY-I-182-1-110.fid
 PROTON DMSO (1192.168.1.100nmrdata\chenxin) test 10



DBY-I-182-1-30.fid
 C13CPD DMSO (1192.168.1.100nmrdata\chenxin) test 8






264-3 #18 RT: 0.10 AV: 1 NL: 1.65E5
T: FTMS + p ESI Full lock ms [80.0000-1200.0000]




5-benzoyl-1-(4-fluorobenzyl)-*N*-(4-(hydroxycarbonyl)benzyl)-1*H*-pyrrole-2-carboxamide (**11d**)


K1-87-10.fid
PROTON DMSO [1192.168, 1.100]umrdata\chenxin\ test 16







264-19 #19 RT: 0.10 AV: 1 NL: 2.76E7
T: FTMS + p ESI Full lock ms [80.0000-1200.0000]








5-benzoyl-1-benzyl-N-(4-(hydroxycarbamoyl)benzyl)-1*H*-pyrrole-2-carboxamide (**11f**)




264-17 #20 RT: 0.11 AV: 1 NL: 9.21E7
T: FTMS + p ESI Full lock ms [80.0000-1200.0000]




5-benzoyl-*N*-(4-(hydroxycarbonyl)benzyl)-1-(4-methoxybenzyl)-1*H*-pyrrole-2-carboxamide (**11g**)




Representative graphs of enzyme activity for **10g** (RBC Company).



Antiproliferative activity graph of representative compound 10g.



Hela cell



SiHa cell